Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study Meeting Abstract
| Authors: | Antonia, S. J.; Brahmer, J. R.; Balmanoukian, A. S.; Kim, D. W.; Kim, S. W.; Ahn, M. J.; Jamal, R.; Jaeger, D.; Ott, P. A.; Ascierto, P. A.; Gregorc, V.; Goldman, J. W.; Blakely, C. M.; Jin, X.; Antal, J.; Gupta, A. K.; Segal, N. H. |
| Abstract Title: | Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Language: | English |
| ACCESSION: | WOS:000411932202169 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.e20504 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: e20504 -- Source: Wos |
